Extravascular hemolysis following the administration of cefamandole.
Hemolytic anemia occurred in a 70-year-old female after a five-day course of intravenous cefamandole. The patient's serum contained an IgG antibody which was reactive with red blood cells which had been coated in vitro with cefamandole but not with uncoated cells. An in vitro assay of allogeneic mononuclear phagocytosis of cefamandole-coated red cells sensitized with the patient's anti-cefamandole indicated that the anti-cefamandole could induce significant phagocytosis. The anti-cefamandole was easily inhibited in vitro by cefamandole as well as by a variety of related cephalosporins indicating broad cross-reactivity, with the antigenic site primarily the 7-amino-cephalosporanic acid nucleus. Penicillins could inhibit the anti-cefamandole but only when using concentrations 3-10 X those of cephalosporins. Eleven examples of anti-penicillin tested failed to react with cefamandole-coated red cells. Screening of 344 random sera from hospitalized patients found only five (1.5%) reactive with cefamandole-coated red cells; three of these sera were also reactive with penicillin-coated red cells. The patient's hemolysis subsided following cessation of the drug. This is the first report of anti-cefamandole-induced hemolytic anemia.
D000368:Aged; D000744:Anemia, Hemolytic, Autoimmune / Q000139:chemically induced*; D002435:Cefamandole / Q000008:administration & dosage / Q000009:adverse effects*; D003176:Complement C3 / Q000276:immunology; D003298:Coombs Test; D004912:Erythrocytes / Q000187:drug effects / Q000276:immunology; D005260:Female; D006241:Haptens / Q000276:immunology; D006801:Humans; D007275:Injections, Intravenous; D007626:Kell Blood-Group System / Q000276:immunology; D008264:Macrophages / Q000276:immunology; D010587:Phagocytosis
D003176:Complement C3; D006241:Haptens; D007626:Kell Blood-Group System; D002435:Cefamandole